Monash Institute of Pharmaceutical Sciences

Servier and Monash Institute of Pharmaceutical Sciences Research Collaboration

Whilst the journey from research to registration is long, Servier is excited at the prospect of bringing to the medical community novel and modern medicines to enable alternatives in managing patients.

The guiding principle of reinvesting all profit from sales into R&D is reflected in Servier's drug discovery and research collaboration with Monash Institute of Pharmaceutical Sciences (MIPS) announced on 30 January 2012.

This collaboration between Servier and MIPS makes use of MIPS acknowledged world-leading capability in the identification of novel GPCR (G Protein-Coupled Receptor) targets and design of new chemical entities which modulate GPCR activity. GPCR represents the largest superfamily of all receptors (approximately 2% of the human genome) and are the targets for approximately 40% of modern medicines. The research program covers various current and potential therapeutic fields including metabolise, cardiology, neurology, psychiatry, rheumatology, and oncology.

This research partnership results in the creation of 15 new, highly skilled jobs for Australia. It will include employee exchange placements between MIPS and Servier, thus contributing to the growth of drug discovery and development capabilities within Australia.

"We are excited to be working with leading Australian experts in GPCR research and to have the opportunity of being involved in the advancement and translation of GPCR-based research into new therapeutic agents for major human diseases."
Director of MIPS, Professor Bill Charman

Click here to visit the MIPS website >